Sugi Predict

Sugi Predict / Compounds / SCHEMBL16617849

SCHEMBL16617849

SCHEMBL16617849

CC(C)(C)OC(=O)N1CCCOS1(=O)=O

nearest known ligand 0.45

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ USP2 O75604 1/20 0.45
▸ SMN1; SMN2 Q16637 1/20 0.45
▸ HSD11B1 P28845 1/20 0.38
▸ CTSK P43235 1/20 0.37
▸ RECQL P46063 1/20 0.37
▸ HPGD P15428 1/20 0.36
▸ EPHX1 P07099 1/20 0.34
▸ PREP P48147 2/20 0.33
▸ CHRM2 P08172 1/20 0.33
▸ CHRM1 P11229 1/20 0.33
▸ CHRM3 P20309 1/20 0.33
▸ MEN1 O00255 2/20 0.32
▸ KMT2A Q03164 2/20 0.32
▸ HSD17B10 Q99714 1/20 0.31
▸ ALDH1A1 P00352 1/20 0.31
▸ MAPT P10636 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL829003 0.90 USP2 (0.47) USP2SMN1; SMN2HSD11B1CTSKRECQL
SCHEMBL17190805 0.79 USP2 (0.42) USP2SMN1; SMN2HSD11B1CTSKRECQL
SCHEMBL4629128 0.74 USP2 (0.41) USP2SMN1; SMN2HSD11B1CTSKRECQL
SCHEMBL31500356 0.73 USP2 (0.34) USP2SMN1; SMN2RECQL
SCHEMBL17873428 0.73 SMN1; SMN2 (0.51) SMN1; SMN2HPGDMEN1KMT2AALDH1A1
SCHEMBL1983350 0.72 USP2 (0.40) USP2SMN1; SMN2HSD11B1CTSKRECQL
SCHEMBL1979622 0.72 USP2 (0.40) USP2SMN1; SMN2HSD11B1CTSKRECQL
SCHEMBL1978328 0.72 USP2 (0.40) USP2SMN1; SMN2HSD11B1CTSKRECQL
SCHEMBL17113045 0.71 USP2 (0.36) USP2SMN1; SMN2HSD11B1CTSKRECQL
SCHEMBL4637067 0.70 HSD11B1 (0.38) USP2SMN1; SMN2HSD11B1CTSKHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260001889-A1 COMPOSITIONS USEFUL FOR MODULATING SPLICING SKYHAWK THERAPEUTICS INC (US) 2026-01-01 — — US disclosed
EP-4514807-B1 COMPOSITIONS USEFUL FOR MODULATING SPLICING SKYHAWK THERAPEUTICS INC (US) 2025-12-17 — — EP disclosed
US-20250340570-A1 COMPOSITIONS USEFUL FOR MODULATING SPLICING SKYHAWK THERAPEUTICS INC (US) 2025-11-06 — — US disclosed
US-20250325687-A1 CONJUGATE COMPRISING TOLL-LIKE RECEPTOR AGONIST MABSOFT THERAPEUTICS SHANGHAI CO LTD (CN) 2025-10-23 — — US disclosed
EP-4619397-A1 SALT-INDUCIBLE KINASES (SIK) INHIBITORS AND METHODS OF USES THEREOF Insilico Medicine IP Limited (HK) 2025-09-24 — — EP disclosed
EP-4522622-A1 COMPOSITIONS USEFUL FOR MODULATING SPLICING Skyhawk Therapeutics, Inc. (US) 2025-03-19 — — EP disclosed
EP-4514807-A1 COMPOSITIONS USEFUL FOR MODULATING SPLICING Skyhawk Therapeutics, Inc. (US) 2025-03-05 — — EP disclosed
EP-4508061-A1 CONJUGATE COMPRISING TOLL-LIKE RECEPTOR AGONIST Mabsoft Therapeutics (Shanghai) Co., Ltd. (CN) 2025-02-19 — — EP disclosed
CN-119365479-A Conjugates comprising Toll-like receptor agonists 慕宝盛科生物医药(上海)有限公司 2025-01-24 — — CN disclosed
US-12195472-B2 Substituted indole Mcl-1 inhibitors VANDERBILT UNIVERSITY (US) 2025-01-14 — — US disclosed
US-20200140447-A1 SUBSTITUTED INDOLE MCL-1 INHIBITORS VANDERBILT UNIVERSITY 2020-05-07 — — US disclosed
EP-3423435-A1 SUBSTITUTED INDOLE MCL-1 INHIBITORS Vanderbilt University (US) 2019-01-09 — — EP disclosed
EP-3055300-B1 ANTAGONISTS OF PROSTAGLANDIN EP3 RECEPTOR PFIZER (US) 2018-03-07 — — EP disclosed
US-9738626-B2 Antagonists of prostaglandin EP3 receptor PFIZER INC. (US) 2017-08-22 — — US disclosed
US-20170174689-A1 SUBSTITUTED INDOLE MCL-1 INHIBITORS VANDERBILT UNIVERSITY 2017-06-22 — — US disclosed
EP-3122353-A1 SUBSTITUTED INDOLE MCL-1 INHIBITORS Vanderbilt University (US) 2017-02-01 — — EP disclosed
US-20160176851-A1 ANTAGONISTS OF PROSTAGLANDIN EP3 RECEPTOR PFIZER INC. (US) 2016-06-23 — — US disclosed
US-9278953-B2 Antagonists of prostaglandin EP3 receptor PFIZER INC. (US) 2016-03-08 — — US disclosed
WO-2015148854-A1 SUBSTITUTED INDOLE MCL-1 INHIBITORS VANDERBILT UNIVERSITY (US) 2015-10-01 — — WO disclosed
US-20150099782-A1 ANTAGONISTS OF PROSTAGLANDIN EP3 RECEPTOR PFIZER INC. (US) 2015-04-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260001889-A1 COMPOSITIONS USEFUL FOR MODULATING SPLICING SF3B1, SF3A1, SF3B5 USP2 3533/4885SMN1; SMN2 333/4885HSD11B1 605/4885
US-20200140447-A1 SUBSTITUTED INDOLE MCL-1 INHIBITORS MCL1, BCL2L1, BCL3 USP2 451/4885SMN1; SMN2 2394/4885HSD11B1 3424/4885
US-20160176851-A1 ANTAGONISTS OF PROSTAGLANDIN EP3 RECEPTOR PTGER3, PTGES3, PTGER2 USP2 2563/4885SMN1; SMN2 4668/4885HSD11B1 2267/4885
US-20250340570-A1 COMPOSITIONS USEFUL FOR MODULATING SPLICING RBM17, SF3A2, SMN1; SMN2 USP2 3243/4885SMN1; SMN2 3/4885HSD11B1 2820/4885
US-20250325687-A1 CONJUGATE COMPRISING TOLL-LIKE RECEPTOR AGONIST TLR3, TLR7, TLR8 USP2 3884/4885SMN1; SMN2 2509/4885HSD11B1 4560/4885
US-12195472-B2 Substituted indole Mcl-1 inhibitors MCL1, BCL2L1, BCL3 USP2 451/4885SMN1; SMN2 2394/4885HSD11B1 3424/4885
US-20150099782-A1 ANTAGONISTS OF PROSTAGLANDIN EP3 RECEPTOR PTGER3, PTGES3, PTGER2 USP2 2563/4885SMN1; SMN2 4668/4885HSD11B1 2267/4885
US-20170174689-A1 SUBSTITUTED INDOLE MCL-1 INHIBITORS MCL1, BCL2L1, BCL3 USP2 451/4885SMN1; SMN2 2394/4885HSD11B1 3424/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.